Maryland-Based Novavax Reaches Agreement For European Commission For Up To 200 Million COVID-19 Vaccine Doses

GAITHERSBURG, Md. (WJZ) — Novavax, a biotechnology institution based successful Gaithersburg, announced Wednesday it has finalized an precocious acquisition statement with the European Commission for up to 200 cardinal doses of its COVID-19 vaccine.

The statement covers the acquisition of up to 100 cardinal doses of the vaccine with the enactment of different 100 cardinal doses done 2023, the institution said. Novavax did not disclose the worth of the purchase.

READ MORE: University Of Maryland Reopens Building After Hazmat Incident, One Wing Remains Closed

Novavax reported 90.4% wide efficacy successful its Phase 3 objective proceedings successful the United States and Mexico. In its Phase 3 trials successful the United Kingdom, the institution reported 89.7% efficacy with 96% efficacy against the archetypal COVID-19 strain.

“As caller coronavirus variants are spreading in Europe and astir the world, this caller declaration with a institution that is already investigating its vaccine successfully against these variants is an further safeguard for the extortion of our population. It further strengthens our wide vaccine portfolio, to the payment of Europeans and our partners worldwide,” Ursula von der Leyen, president of the European Commission, said successful a statement.

The vaccine, named NVX-CoV2373, is simply a protein-based vaccine campaigner engineered from the familial series of the archetypal strain of SARS-CoV-2, the microorganism that causes COVID-19 disease, institution officials said.

READ MORE: Testing At Aberdeen Proving Ground Causes Loud Booms In Harford, Baltimore County

“We convey the European Commission for their concern successful this important measurement to grow vaccine options for the citizens of Europe and globally arsenic we enactment to bring the archetypal COVID-19 macromolecule subunit vaccine to the market,” said Stanley Erck, Novavax’s president and CEO. “With objective information from our trials showing beardown efficacy against Variants of Concern and Variants of Interest, we judge that our vaccine campaigner volition play a captious relation successful the effort to assistance power the pandemic successful the EU and different regions successful the world.”

The Novavax vaccine is not approved for usage successful the United States.

MORE NEWS: Seven Baltimore City Fire Department Take-Home Vehicles Assigned To Members Who Live Out Of State, Report Finds

CBS Baltimore Staff